[Featured Stock] JLK, Brain MR Analysis Solution Applies for US FDA Approval... "Accelerating Entry into the US Market"

JLK is showing strong performance. The news that it has completed the application for approval from the U.S. Food and Drug Administration (FDA) for its brain MR perfusion imaging analysis solution (JLK-PWI) appears to have had an impact.

As of 9:51 AM on the 12th, JLK was trading at 13,990 KRW, up 1,030 KRW (7.95%) compared to the previous trading day.

The JLK-PWI, for which JLK is currently pursuing FDA approval, is a solution that automatically analyzes brain MR perfusion images and provides quantitative indicators of the core area of cerebral infarction and regions with reduced brain perfusion. This solution operates based on diffusion-weighted MR imaging (DWI) and perfusion-weighted MR imaging (PWI), automatically analyzing essential information for determining treatment plans for acute cerebral infarction and providing it to medical professionals.

By utilizing this solution, medical professionals can quantitatively identify brain areas that can be saved through vascular recanalization, enabling them to accurately and quickly grasp information necessary for deciding treatment plans for critical stroke patients. In particular, it helps improve the prognosis of acute cerebral infarction patients by allowing rapid decisions on emergency surgery (procedures), including thrombectomy (EVT) for hyperacute cerebral infarction patients.

The company plans to accelerate its entry into the U.S. market by leveraging its cutting-edge technology in AI-based stroke diagnosis and further strengthen its position in the global stroke treatment market.

This content was produced with the assistance of AI translation services.